Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
158.4 USD | +3.28% | +8.20% | -19.68% |
Apr. 23 | Barclays Adjusts Zoetis' Price Target to $230 From $260, Keeps Overweight Rating | MT |
Apr. 22 | Jefferies Lowers Zoetis Price Target to $200 from $220 | MT |
Business Summary
- pets (64.4%): cats and dogs (94.9% of net sales) and horses (5.1%);
- livestock (34.5%): cattle (51.6% of sales), swine (20.2%), poultry (17.1%), fish (7.6%) and other (3.5%);
- other (1.1%).
Net sales break down by family of products into parasiticides (23%), vaccines (21.3%), dermatological products (16.4%), anti-infectives (13.4%), medical food additives (4.5%), diagnostic products (4.4%) and other (17%).
At the end of 2022, the group has 29 production sites worldwide.
The United States accounts for 53.4% of net sales.
Number of employees: 14,100
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Parasiticides
22.8
%
| 1,860 | 23.0 % | 1,947 | 22.8 % | +4.68% |
Vaccines
20.7
%
| 1,718 | 21.3 % | 1,771 | 20.7 % | +3.08% |
Dermatology
16.7
%
| 1,329 | 16.4 % | 1,427 | 16.7 % | +7.37% |
Other Pharmaceuticals
15.0
%
| 1,043 | 12.9 % | 1,280 | 15.0 % | +22.72% |
Anti-infectives
12.4
%
| 1,081 | 13.4 % | 1,057 | 12.4 % | -2.22% |
Animal Health Diagnostics
4.4
%
| 353 | 4.4 % | 376 | 4.4 % | +6.52% |
Medicated Feed Additives
4.1
%
| 360 | 4.5 % | 354 | 4.1 % | -1.67% |
Other Non-pharmaceuticals
3.0
%
| 250 | 3.1 % | 254 | 3.0 % | +1.60% |
Contract Manufacturing and Human Health
0.9
%
| 86 | 1.1 % | 78 | 0.9 % | -9.30% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
53.3
%
| 4,313 | 53.4 % | 4,555 | 53.3 % | +5.61% |
Other Emerging Markets
9.2
%
| 758 | 9.4 % | 784 | 9.2 % | +3.43% |
Other Developed Markets
6.0
%
| 468 | 5.8 % | 512 | 6.0 % | +9.40% |
Brazil
4.6
%
| 330 | 4.1 % | 393 | 4.6 % | +19.09% |
Australia
3.8
%
| 289 | 3.6 % | 323 | 3.8 % | +11.76% |
China
3.7
%
| 382 | 4.7 % | 320 | 3.7 % | -16.23% |
United Kingdom
3.2
%
| 235 | 2.9 % | 277 | 3.2 % | +17.87% |
Canada
3.0
%
| 238 | 2.9 % | 255 | 3.0 % | +7.14% |
Germany
2.4
%
| 176 | 2.2 % | 202 | 2.4 % | +14.77% |
Mexico
1.9
%
| 136 | 1.7 % | 162 | 1.9 % | +19.12% |
Japan
1.8
%
| 173 | 2.1 % | 158 | 1.8 % | -8.67% |
France
1.7
%
| 126 | 1.6 % | 142 | 1.7 % | +12.70% |
Chile
1.6
%
| 141 | 1.7 % | 140 | 1.6 % | -0.71% |
Spain
1.4
%
| 118 | 1.5 % | 122 | 1.4 % | +3.39% |
Italy
1.4
%
| 111 | 1.4 % | 121 | 1.4 % | +9.01% |
Global
0.9
%
| 86 | 1.1 % | 78 | 0.9 % | -9.30% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Kristin Peck
CEO | Chief Executive Officer | 52 | 11-12-31 |
Wetteny Joseph
DFI | Director of Finance/CFO | 52 | 21-05-31 |
Mike McFarland
CTO | Chief Tech/Sci/R&D Officer | - | 10-12-31 |
Robert Polzer
CTO | Chief Tech/Sci/R&D Officer | 56 | 14-12-31 |
Wafaa Mamilli
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-12-31 |
Steven Frank
IRC | Investor Relations Contact | - | 15-02-28 |
William Dorsey
PRN | Corporate Officer/Principal | - | - |
Ester Banque
PRN | Corporate Officer/Principal | - | 23-07-09 |
Abhay Nayak
PRN | Corporate Officer/Principal | - | - |
Roxanne Lagano
HRO | Human Resources Officer | 59 | 12-09-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 71 | 12-12-31 | |
Louise Parent
BRD | Director/Board Member | 73 | 13-07-31 |
Robert Scully
BRD | Director/Board Member | 74 | 13-05-31 |
Kristin Peck
CEO | Chief Executive Officer | 52 | 11-12-31 |
Paul Bisaro
BRD | Director/Board Member | 63 | 15-04-30 |
Frank D'Amelio
BRD | Director/Board Member | 66 | 12-06-30 |
Sanjay Khosla
BRD | Director/Board Member | 71 | 13-05-31 |
Gregory Norden
BRD | Director/Board Member | 66 | 12-12-31 |
Director/Board Member | 55 | 22-07-24 | |
Willie Reed
BRD | Director/Board Member | 69 | 14-03-03 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 500,471,090 | 455,877,565 ( 91.09 %) | 43,523,885 ( 8.697 %) | 91.09 % |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Pharmaq AS
Pharmaq AS Pharmaceuticals: MajorHealth Technology PHARMAQ AS operates as a veterinary pharmaceutical company. It provides health products to the global aquaculture industry. The company was founded on July 23, 2004 and is headquartered in Overhalla, Norway. |
Pharmaceuticals: Major
|
Zoetis India Ltd.
Zoetis India Ltd. Pharmaceuticals: MajorHealth Technology Founded in 2007, Zoetis India Ltd. is a subsidiary of Zoetis, Inc. that manufactures vaccines and injectable biologic medicines. The private company is based in Mumbai, India. |
Pharmaceuticals: Major
|
Zoetis Treasury Center BV
| |
Zoetis Belgium SA
Zoetis Belgium SA BiotechnologyHealth Technology Part of Zoetis, Inc., Zoetis Belgium SA is a Belgian company that manufactures animal vaccines and prescription medicines. The private company is based in Louvain-La-Neuve, Belgium. |
Biotechnology
|
Zoetis Singapore Pte Ltd.
| |
Zoetis Vietnam LLC
Zoetis Vietnam LLC Pharmaceuticals: MajorHealth Technology Zoetis Vietnam LLC engages in the distribution of medicine and vaccinations for pets and livestocks. The company was founded on August 16, 2013 and is headquartered in Ho Chi Minh City, Vietnam. |
Pharmaceuticals: Major
|
Zoetis Pharmaceutical Research Pvt Ltd.
| |
Zoetis Korea Ltd.
Zoetis Korea Ltd. Pharmaceuticals: MajorHealth Technology Part of Zoetis, Inc., Zoetis Korea Ltd. is a South Korean company that manufactures veterinary medicinal preparations. The private company is located in South Korea. |
Pharmaceuticals: Major
|
Pharmaq Vietnam Co. Ltd.
|
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.30% | 70.08B | |
+18.88% | 3.52B | |
-3.62% | 3.11B | |
-2.87% | 1.38B | |
-15.41% | 1.37B | |
-4.30% | 1.24B | |
-27.74% | 1.21B | |
-13.54% | 1.13B | |
-2.99% | 1.02B | |
-10.35% | 795M |
- Stock Market
- Equities
- ZTS Stock
- Company Zoetis Inc.